Cargando…
Tumor Restrictions to Oncolytic Virus
Oncolytic virotherapy has advanced since the days of its conception but therapeutic efficacy in the clinics does not seem to reach the same level as in animal models. One reason is premature oncolytic virus clearance in humans, which is a reasonable assumption considering the immune-stimulating natu...
Autores principales: | Vähä-Koskela, Markus, Hinkkanen, Ari |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423468/ https://www.ncbi.nlm.nih.gov/pubmed/28548066 http://dx.doi.org/10.3390/biomedicines2020163 |
Ejemplares similares
-
Oncolytic viruses in cancer therapy
por: Vähä-Koskela, Markus J.V., et al.
Publicado: (2007) -
Oncolytic adenoviruses: A potent form of tumor immunovirotherapy
por: Cerullo, Vincenzo, et al.
Publicado: (2012) -
Oncolytic adenovirus improves anti-tumor efficacy of adoptive T cell therapy by breaking tumor-induced immunosuppression and peripheral tolerance
por: Tähtinen, Siri, et al.
Publicado: (2015) -
Attenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory Beagles
por: Autio, Karoliina P. M., et al.
Publicado: (2015) -
Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity
por: Hirvinen, Mari, et al.
Publicado: (2016)